Wedbush Predicts AnaptysBio’s FY2024 Earnings (NASDAQ:ANAB)

AnaptysBio, Inc. (NASDAQ:ANAB) – Wedbush increased their FY2024 EPS estimates for shares of AnaptysBio in a report released on Tuesday, November 5th. Wedbush analyst D. Nierengarten now anticipates that the biotechnology company will post earnings per share of ($5.22) for the year, up from their previous forecast of ($6.65). Wedbush has a “Outperform” rating and a $42.00 price target on the stock. The consensus estimate for AnaptysBio’s current full-year earnings is ($6.84) per share. Wedbush also issued estimates for AnaptysBio’s Q4 2024 earnings at ($0.81) EPS, Q1 2025 earnings at ($0.54) EPS, Q2 2025 earnings at ($0.55) EPS, Q3 2025 earnings at ($0.57) EPS, Q4 2025 earnings at ($0.59) EPS, FY2025 earnings at ($2.25) EPS, FY2026 earnings at ($2.38) EPS, FY2027 earnings at ($2.82) EPS and FY2028 earnings at ($3.53) EPS.

A number of other analysts have also weighed in on ANAB. Guggenheim raised their target price on AnaptysBio from $75.00 to $90.00 and gave the company a “buy” rating in a research note on Monday, October 21st. JPMorgan Chase & Co. raised their price objective on shares of AnaptysBio from $69.00 to $75.00 and gave the company an “overweight” rating in a research report on Wednesday, August 7th. HC Wainwright reduced their target price on shares of AnaptysBio from $55.00 to $52.00 and set a “buy” rating on the stock in a research report on Wednesday. UBS Group raised their price target on shares of AnaptysBio from $23.00 to $33.00 and gave the company a “neutral” rating in a report on Wednesday, October 30th. Finally, Truist Financial boosted their price objective on shares of AnaptysBio from $20.00 to $30.00 and gave the stock a “hold” rating in a research report on Thursday, August 15th. Two equities research analysts have rated the stock with a hold rating and ten have assigned a buy rating to the company. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $55.45.

AnaptysBio Stock Performance

Shares of ANAB opened at $21.31 on Friday. The company has a market cap of $584.53 million, a price-to-earnings ratio of -3.36 and a beta of -0.24. The stock has a fifty day moving average price of $32.66 and a two-hundred day moving average price of $29.84. AnaptysBio has a 52-week low of $13.36 and a 52-week high of $41.31.

AnaptysBio (NASDAQ:ANAB) last announced its earnings results on Tuesday, November 5th. The biotechnology company reported ($1.14) EPS for the quarter, topping the consensus estimate of ($1.72) by $0.58. The business had revenue of $30.02 million for the quarter, compared to the consensus estimate of $7.92 million. AnaptysBio had a negative return on equity of 255.68% and a negative net margin of 558.25%.

Institutional Trading of AnaptysBio

A number of large investors have recently made changes to their positions in the company. Frazier Life Sciences Management L.P. lifted its holdings in AnaptysBio by 140.7% during the second quarter. Frazier Life Sciences Management L.P. now owns 2,165,591 shares of the biotechnology company’s stock worth $54,270,000 after acquiring an additional 1,265,891 shares in the last quarter. Jennison Associates LLC bought a new stake in shares of AnaptysBio in the third quarter worth about $8,874,000. StemPoint Capital LP raised its position in shares of AnaptysBio by 499.0% during the first quarter. StemPoint Capital LP now owns 269,548 shares of the biotechnology company’s stock worth $6,070,000 after purchasing an additional 224,548 shares during the period. Victory Capital Management Inc. lifted its holdings in shares of AnaptysBio by 677.9% during the 3rd quarter. Victory Capital Management Inc. now owns 237,250 shares of the biotechnology company’s stock valued at $7,948,000 after purchasing an additional 206,750 shares in the last quarter. Finally, Assenagon Asset Management S.A. grew its position in shares of AnaptysBio by 55.1% in the 3rd quarter. Assenagon Asset Management S.A. now owns 475,446 shares of the biotechnology company’s stock valued at $15,927,000 after purchasing an additional 168,813 shares during the period.

Insiders Place Their Bets

In other news, insider Paul F. Lizzul sold 1,500 shares of the stock in a transaction on Monday, September 23rd. The stock was sold at an average price of $38.67, for a total value of $58,005.00. Following the transaction, the insider now owns 15,398 shares of the company’s stock, valued at $595,440.66. This represents a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. In related news, insider Paul F. Lizzul sold 1,500 shares of the stock in a transaction that occurred on Monday, September 23rd. The shares were sold at an average price of $38.67, for a total value of $58,005.00. Following the sale, the insider now directly owns 15,398 shares in the company, valued at $595,440.66. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, CFO Dennis Mulroy sold 12,220 shares of the business’s stock in a transaction that occurred on Monday, September 16th. The shares were sold at an average price of $39.91, for a total transaction of $487,700.20. Following the transaction, the chief financial officer now owns 4,744 shares of the company’s stock, valued at approximately $189,333.04. This represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders sold 22,440 shares of company stock valued at $892,936. Company insiders own 33.70% of the company’s stock.

About AnaptysBio

AnaptysBio, Inc, a clinical-stage biotechnology company, focuses in delivering immunology therapeutics. Its products include Rosnilimab, an IgG1 antibody that targets PD-1+ T cells, resulting in their agonism or depletion, broadly impacting pathogenic drivers of autoimmune and inflammatory diseases; and ANB032, a non-depleting antibody that binds to the BTLA checkpoint receptor and inhibits activated T cell proliferation; ANB033, a novel anti-CD122 antagonist antibody that targets the shared common beta subunit of the receptors for IL-15 and IL-2; ANB101, a BDCA2 modulator antibody that specifically targets plasmacytoid dendritic cells (pDCs); and Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 development for the treatment of generalized pustular psoriasis.